You are here

Calder Biosciences Inc.

Company Information
Address
140 58TH ST STE 8J
BROOKLYN, NY 11220-2539
United States


https://www.calderbiosciences.com/

Information

UEI: YZYMDHZG3ZN7

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. An RSV Prefusion F Vaccine that Overcomes Immunosenescence

    Amount: $1,928,617.00

    Respiratory Syncytial Virus (RSV) infection in the elderly causes great human suffering due to hospitalization and death, and is considered a societal burden similar to that of seasonal influenza. Vac ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. An RSV Prefusion F Vaccine that Overcomes Immunosenescence

    Amount: $299,740.00

    Respiratory Syncytial VirusRSVinfection in the elderly causes great human suffering due to hospitalization and deathand is considered a societal burden similar to that of seasonal influenzaVaccines fo ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA

    Amount: $2,861,512.00

    An Influenza pandemic remains an acute threat to world health; and stockpiling a universally protective Influenza vaccine provides a strong defense against this potential catastrophe. The hemagglutini ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  4. An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination

    Amount: $599,742.00

    A Respiratory Syncytial VirusRSVvaccine is not yet availableAvatar is developing a noveldi tyrosine crosslinkedconformationally locked preF subunit immunogenDT preFthatformulated with an adjuvantwill ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government